ABSTRACT
Infanrix-IPV (GSK, Belgium) is a diphtheria, tetanus, acellular pertussis, and inactivated poliovirus combination vaccine (DTaP-IPV) licensed in many countries including Korea. In accordance with Korean regulations, we conducted a post-marketing surveillance (PMS) to evaluate the safety of DTaP-IPV administered to Korean children in routine immunization schedules. Children aged <7 years receiving at least one dose of DTaP-IPV either as part of a primary (3-dose) vaccination series or as a subsequent booster were enrolled. Adverse events (AEs), adverse drug reactions (ADRs) and serious AEs (SAEs) were recorded after each dose during the 30-day post-vaccination follow-up period. Among a total of 639 children, 289 subjects (45.2%) experienced AEs, mostly (79.2%) assessed as being unlikely to be related to the vaccination. ADRs were reported in 13.0% of subjects. Fever was the most commonly reported expected AE (11.9% of subjects) and also the most commonly reported expected ADR (8.5% of subjects). No obvious association between AE incidence and vaccine dose sequence was apparent. An unexpected AE was seen in 32.9% of children, and unexpected ADRs were far less common (1.9%). Thirty-four SAEs were recorded in 26 subjects (4.1%), in two of whom a causal association with the vaccine could not be excluded, although both resolved quickly. Data from this PMS indicate that DTaP-IPV has an acceptable safety profile when given to Korean children in accordance with local prescribing recommendations in routine childhood immunization. ClinicalTrials.gov identifier: NCT01568060
Acknowledgments
The authors would like to acknowledge the investigators and their clinical teams for their contribution to the study and their support and care of participants/patients, as well as the children and their parent/guardian for their participation. The authors also would like to thank Business & Decision Life Sciences platform for editorial assistance and publication coordination, on behalf of GSK. Nathalie Arts coordinated manuscript development and editorial support. The authors thank Iain O’Neill (freelance on behalf of GSK) for providing medical writing support.
Author contributions
All authors participated in the study design and/or implementation, analysis, and interpretation of the data. All authors had full access to the data, participated in manuscript development and gave final approval before submission
Disclosure of potential conflicts of interest
SJK, JC, RS, JHK and RD are employees of the GSK group of companies. SJK, JC, RS and JHK hold shares in the GSK group of companies. YKK and SML have nothing to disclose.
Trademark section
Infanrix-IPV is a trade mark owned by or licensed to the GSK group of companies.
Supplementary material
Supplemental data for this article can be accessed on the publisher’s website.